1. Treatment Algorithms in Melanoma: Past, Present, and Future

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Pembrolizumab vs Ipilimumab: OS Results

6. Combination Therapy: 3-Year OS

7. Combination Therapy vs Monotherapy With a PD-1 Inhibitor

8. IDO

9. IDO Inhibition: Epacadostat

10. Potential Mechanisms of Combination Approaches With IDO Inhibitors

11. IDO Inhibition: Epacadostat

12. IDO Inhibition: Indoximod

13. LAG-3

14. LAG-3 Inhibition

15. T-Vec + Ipilimumab

16. T-Vec + Pembrolizumab

17. Costimulatory Molecules

18. When Is It Safe to Stop Therapy?

19. Data on Stopping Therapy From NSCLC

20. Treatment Beyond Progression

21. Sequencing

22. Long-Term Survival Data for Targeted Therapy

23. Brain Metastases

24. Combining Targeted Therapy With Checkpoint Inhibition

25. Adjuvant Immunotherapy

26. Adjuvant Therapy With Nivolumab

27. Treat Early or Later?

28. Adjuvant Therapy With Targeted Therapies

29. Treating Patients With Stage III Melanoma

30. Concluding Remarks